This study reviewed evidence of the effectiveness and safety of oral CBD at doses below 400mg. It was published in October 2022 in the journal Clinical and Translational Science.
The authors state that "there is sufficient clinical trial evidence to support the use of high oral doses of CBD (e.g., 10–50 mg/kg) in treating intractable childhood epilepsies." For a 62kg adult, that means a dose of 620 to 3100mg per day. They reviewed studies that involved low doses (below 400mg per day) of CBD in adults only, not children.
35 qualifying studies were included in their efficacy (effectiveness) analysis. 29 were double-blind, placebo-controlled trials and 6 were open label trials. Open label trials were given lower weights in their analysis. They focused on the following categories for patient conditions:
- Chronic Pain
The evidence they found showed CBD effectiveness mostly at doses over 300mg per day.
In the authors' words:
Therapeutic benefits of CBD became more clearly evident at doses greater than or equal to 300 mg.
At doses of 300–400 mg, there is evidence of efficacy with respect to reduced anxiety, as well as anti-addiction effects in drug-dependent individuals.
More marginal and less consistent therapeutic effects on insomnia, neurological disorders, and chronic pain were also apparent.
CBD appears exceptionally safe, with very few concerns even at the highest dose range considered (>300–400 mg);
The full text review study is here at the American Society for Clinical Pharmacology and Therapeutics website.